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ABSTRACT 
Long-term outcome after joint bleeds in VWD (VWF activity≤30IU/dL) could differ from moderate or 
severe haemophilia A (FVIII 1-5IU/dL or FVIII<1IU/dL). We performed a post-hoc analysis on 
Haemophilia Joint Health Scores (HJHS, 0-124), X-ray Pettersson scores (PS, 0-13/joint) and the 
Haemophilia Activities List (HAL, 0-100), using multivariable regression to adjust for age (rate-ratio or 
odds-ratio [95% confidence interval]). We included 48 VWD (median age 47yrs, type 3 VWD n=19), 39 
moderate HA (median 39yrs) and 59 severe HA patients (median 25yrs) with documented joint 
bleeds. VWD-patients suffered repeated bleeding (lifetime>5/joint) less often than moderate and 
severe HA patients (52% vs. 77% vs. 98%). HJHS and PS in VWD were similar to moderate HA (median 
HJHS 5 vs. 6, RR 0.9[0.5-1.4] and PS>3 of ≥1 joint OR 0.3[0.1-1.4]), but better than in severe HA 
patients (median HJHS 5 vs. 9, RR 1.8[1.1-2.9]; PS>3 in any joint OR 0.1[0.0-0.3]). Self-reported 
limitations in activities were comparable across VWD, moderate HA (HAL score<95: 67% vs. 49%; OR 
1.4[0.5-3.6]) and young adults with severe HA (67% vs. 48%; OR 1.7[0.7-4.4]). Despite fewer joint 
bleeds, joint outcome after joint bleeds was similar in VWD and moderate HA patients. Type 3 VWD 
patients had worst joint outcome, comparable to younger intensively treated severe HA patients. 
Limitations in activities occurred as often in VWD as in both moderate and severe HA.  
Key words: Von Willebrand disease, joint bleed, arthropathy, haemophilia A, HJHS, Pettersson, HAL 
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INTRODUCTION 
Von Willebrand disease (VWD) is the most common inherited bleeding disorder with a prevalence of 
1/100 – 1/10.000, followed by haemophilia A (HA), with a prevalence of 1/5000 males.(1;2) Deficient 
or dysfunctional Von Willebrand Factor (VWF) causes predominantly mucocutaneous bleeding 
symptoms in VWD.(3) In HA, bleeding is due to a deficiency of clotting factor VIII (FVIII). Greatly 
reduced FVIII levels also occur in more severe VWD, since VWF is a carrier protein for FVIII in the 
circulation. In the Willebrand in the Netherlands (WiN) study, a nationwide cohort study on more 
than 800 VWD patients (VWF activity ≤30 IU/dL), 6% of the participants had very low FVIII levels <10 
IU/dL at diagnosis.(3;4) In HA, low FVIII leads to recurrent joint bleeds that cause damage to the 
cartilage and synovium, resulting in arthropathy.(5) Haemophilic arthropathy is characterized by pain, 
physical restrictions and limitations in both activities and participation.(6) Current haemophilia 
treatment aims to prevent this complication by regular prophylactic FVIII infusions starting at young 
age.(7) Preventing joint bleeds by VWF/FVIII prophylaxis is not a clearly defined treatment goal in 
VWD.(8)  
Joint bleeds occur in approximately half of the patients with type 3 VWD, characterized by the 
absence of VWF and strongly reduced FVIII levels, but also in 5-10% of type 1 and type 2 VWD 
patients.(4) Especially in VWD patients with FVIII levels <10 IU/dL, recurrent joint bleeds can result in 
arthropathy.(9-13) Therefore, it is important to assess clinical outcome after joint bleeds, in order to 
identify arthropathy early and provide optimal treatment to prevent further limitations in activities, 
preserve social participation and quality of life.(14) The ‘Haemophilia Joint Health Score’ (HJHS) is a 
widely used physical examination score, developed and proven valid to measure joint health in 
haemophilia.(15-17) The HJHS was recently validated in VWD.(18) In addition, joint X-rays can be 
used to detect arthropathy in both HA and VWD.(10;11;15;18-20) The ‘Haemophilia Activity List’ 
(HAL) patient questionnaire is used to assess self-perceived limitations in activities and aspect of 
participation and validated in VWD.(21;22)  
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In contrast to haemophilia, a limited number of studies addressed arthropathy in VWD.(4;9) A 
comparison of joint outcome between patients with VWD and haemophilia can help to obtain more 
insight into the long-term consequences of joint bleeds in VWD. The aim of this cross-sectional study 
is to compare differences in joint outcome after joint bleeds between adult patients with VWD and 
HA. We hypothesized that joint outcome after joint bleeds in patients with VWD would be 
comparable to moderate HA, but better than in severe HA, because of the higher incidence of 
recurrent joint bleeds in the latter patient category.  
 
METHODS 
The original studies were approved by the Medical Research Ethics Committee of the University 
Medical Center Utrecht in the Netherlands. Informed consent included permission for subsequent 
analyses of joint outcome data.  
Study design 
We conducted a post hoc analysis on joint outcome data from three cross-sectional studies, one on 
VWD and two on moderate and severe HA.(13;17;23) The data on VWD patients were obtained from 
the WiN study.(24) Self-reported joint bleeds in the WiN study questionnaire were verified by 
obtaining the treatment history from medical files.(4) Subsequently these patients were contacted 
and joint assessment took place within the nationwide Willebrand Arthropathy Study between 
August 2013 and July 2015.(13) Data on moderate and severe HA were obtained from two cohort 
studies, previously conducted at the ‘Van Creveldkliniek’, a haemophilia treatment center in the 
University Medical Center Utrecht, The Netherlands, between June 2006-July 2009 and January 2006-
July 2009, respectively.(13;17;23) 
Patients  
The selection procedure is shown in Figure 1. Adults ≥18 years with VWD (VWF activity ≤30 IU/dL) 
and moderate HA (FVIII 1-5 IU/dL) or severe HA (FVIII <1 IU/dL) and verified joint bleeds were 
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selected from the three original studies.(13;17;23) Within these studies there were no restrictions in 
year of birth at inclusion regarding the VWD and moderate HA patients. However the inclusion of 
severe HA patients was restricted to those born between January 1, 1970, and January 1, 1994 
because the original study assessed outcome after the availability of clotting factor concentrates. We 
verified a history of joint bleeds by recording medical file documentation on treatment of joint bleeds 
with desmopressin or clotting factor concentrate. HA patients with comorbid VWD were excluded 
(n=1). Joint assessment, including X-rays, took place during one study visit in the Willebrand 
Arthropathy Study, of which the results have been published recently.(13) Within the two single 
center haemophilia studies, joint assessment was conducted during routine visits to the ‘Van 
Creveldkliniek’ University Medical Center Utrecht, the Netherlands.(17;23) Because in severe HA joint 
X-rays were performed routinely every five years and in moderate HA if indicated, independently 
from the HJHS, only Pettersson scores obtained 2.5 years before or after HJHS assessment were 
included in the analyses. This cut off was chosen based on previous publications showing a median 
change in Pettersson score of 0.4 points/yr in severe haemophilia patients and an inter-observer 
agreement of the Pettersson score of 1 point.(25;26)Patients with clinically relevant FVIII factor 
inhibitors had been excluded from these studies and did not occur within the VWD cohort, VWF 
inhibitors had not been excluded.(13) 
We retrieved data on the number of joint bleeds and history of orthopedic surgery from the medical 
files of the HA and VWD patients. We recorded the lifetime number of joint bleeds in ankles, elbows 
and knees as 0, 1-5 or >5 joint bleeds at joint level, from birth until the age the HJHS had been 
performed. The reason to do so was twofold: first, because more than five joint bleeds are predictive 
of arthropathy and second, because of the limited reliability of medical file data to determine the 
number of joint bleeds per joint in patients with frequently recurrent joint bleeds.(4;13;27) Study 
definitions are provided in the Supplemental material.  
Outcome parameters 
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The outcome parameters cover all three domains of the International Classification of Functioning, 
Disability and Health (ICF) standard as widely used by the WHO: the body structure and function level 
(HJHS and joint X-rays), as well as activity level and participation level (HAL).(28) 
The primary outcome parameter was joint health as measured by the HJHS, a physical examination 
assessment scale of 11-items. One physiotherapist (PK) performed all HJHS assessments within the 
three included studies. The assessment includes several items of assessment of elbows, knees and 
ankles: range of motion (ROM), crepitus on motion, (duration of) swelling, muscle atrophy, pain, 
strength and a global gait score. This leads to a total score ranging from 0-124 points; a higher score 
indicates worse joint health.(16) There has been limited validation of the HJHS in adults with 
haemophilia and in women. (15) We have previously validated the HJHS within a large cohort of  
adult VWD patients, including 40% females.(22) 
Secondary outcome parameters were osteochondral changes of elbows, ankles and knees on joint X-
rays, assessed by the Pettersson score (PS, performed by radiologists, range 0-13 per joint), and self-
reported limitations in activities, assessed by the HAL questionnaire.(21;29)  
Based on the Limits of Agreement of the PS joint in hemophilia patients, we demarcated a PS >3 of 
one or more joints as radiologic joint changes indicating arthropathy.(26) Arthropathy was defined as 
a HJHS ≥10 or PS >3 of one or more joints in accordance to the Willebrand Arthropathy Study.(13) The 
PS was assessed by two different observers in the VWD and haemophilia studies. High agreement 
between these two observers was previously established (intra-class correlation 0.88; 0.32–0.97).(30) 
The HAL asks about a wide variety of functional activities, including items on participation.(31);(21) 
The normalized total score ranges from 0-100, a score of 100 means that the participant does not 
experience functional limitations. For statistical analyses, we dichotomized the total HAL score into 
‘no limitations in activities’ (HAL ≥95) and ‘some limitations in activities’ (HAL <95), based on the 
median HAL score in patients with severe haemophilia.(14)  
Statistical analyses 
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We used IBM SPSS version 23 for the statistical analyses. To analyse differences in the HJHS between 
VWD and HA we used negative binomial regression analysis because of the skewed distribution of the 
HJHS and the excess of zeroes.(32) To compare the HAL total and sub-scores between VWD and HA 
we used the Mann-Whitney U (MWU) test. To analyse differences in the cumulative number of joint 
bleeds, radiological joint changes and limitations in activities between VWD and HA we used logistic 
regression with the cumulative number of joint bleeds >5, PS >3 and total HAL score <95 as 
dependent variables and diagnosis as independent variable with VWD as reference category.  
We performed multivariable analysis to adjust for age on all outcome parameters and to correct for 
VWF inhibitors in the analysis of the primary endpoint. We did not account for the use of prophylaxis 
in the analyses to reflect joint outcome in current clinical practice. Rate ratios and odds ratios (RR and 
OR) are presented with 95% confidence intervals.  
We considered missing data (Figure 1) as missing completely at random and did not use imputation 
methods. X-ray data were missing from a large proportion of HA patients, because only X-rays 
performed within 2.5 years before or after assessment of the HJHS were included.(17;23) We 
performed sensitivity analysis to explore differences in joint status (HJHS) between HA patients with 
and without available PS.  
A planned subgroup analysis was performed to explore differences in HJHS, HAL and PS between the 
patients with type 3 VWD and moderate or severe HA. Within the VWD patients we explored 
whether very low VWF activity <5 IU/dL or FVIII levels <10 IU/dL were associated with worse HJHS 
scores.  
 
 
RESULTS 
Baseline characteristics and medical file data  
In total 146 patients with a history of verified joint bleeds were included in the analyses (Figure 1). 
The study cohort consisted of 48 patients with VWD (38% with historically lowest VWF activity <5 
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IU/dL, 46% with historically lowest FVIII levels <10 IU/dL), 39 patients with moderate HA and 59 
patients with severe HA. The baseline characteristics of these patients are depicted in Table 1. The 
patients with VWD were older during joint assessment compared to those with HA (median age 47 in 
VWD vs. 39 in moderate HA vs. 25 years in severe HA). The VWD cohort included 40% females and 8 
type 1, 21 type 2 and 19 type 3 VWD patients. The type 2 VWD patients mainly had subtype 2A 
(n=15) or 2B (n=5) (Table 1). A large majority of the severe HA patients used prophylaxis (85%) and 
home treatment with clotting factor concentrates, in contrast to the VWD and moderate HA patients. 
The joint outcome data are summarized in Table 2 and 4. Overall, a significantly smaller proportion of 
VWD patients had a history of more than five joint bleeds in the same joint (52%) compared to both 
moderate and severe HA patients, independent of age differences (77% and 98% respectively; OR 
0.2[0.1-0.7] and 0.1[0.1-0.4] compared to VWD). Orthopaedic surgery because of arthropathy after 
joint bleeds took place in approximately one in five patients across all three patient groups. The first 
joint bleed occurred at a significantly higher age in VWD compared to HA (median age 10 vs. 4 vs. 2 
years, p<0.01 compared to both moderate and severe HA, respectively). 
Primary outcome parameter: joint health at physical examination and occurrence of arthropathy 
HJHS results were available in 47 VWD, 32 moderate and 58 severe HA patients with verified joint 
bleeds (Figure 2). Table 3 shows the results of the multivariable analyses. Joint health was 
comparable between the patients with VWD and those with moderate HA (median HJHS 5 vs. 6; age 
adjusted RR 0.9[0.5-1.4]). Patients with VWD scored better on the HJHS than the younger and more 
intensively treated severe HA patients (median HJHS 5 vs. 9; age adjusted RR 1.8[1.1-2.9]). This 
difference hardly changed after correction for the three VWF inhibitor patients (Table 3).  
Secondary outcome parameter: radiologic joint changes 
X-ray Pettersson scores (PS) were available from 115 joints of 46 patients with VWD, 34 joints of 10 
patients with moderate HA and 187 joints of 40 patients with severe HA (Table 4). Sensitivity analysis 
demonstrated that the moderate and severe HA patients with and without available X-rays had 
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comparable HJHS scores (age adjusted RR 0.9[0.4-2.4] and 1.3[0.7-2.3], respectively). Patients with 
VWD less often had arthropathy on X-ray (PS >3 of at least one joint) compared to those with severe 
HA (26% vs. 68%, age adjusted OR 0.1[0.0-0.3]), particularly in the ankles (Table 4). In contrast, 
arthropathy on X-ray after verified joint bleeds was observed in a similar proportion of patients with 
VWD and moderate HA (Table 3A). A PS >3 was strongly associated with a history of > 5 joint bleeds 
across all patient groups; only one VWD patient and none of the HA patients had a PS >3 and a 
history of 5 or less joint bleeds. 
Secondary outcome parameter: functional impact of arthropathy 
HAL results were available from 48 VWD, 35 moderate and 46 severe HA patients with verified joint 
bleeds and are depicted in Table 2. Self-reported limitations in activities, according to the HAL total 
score, did not differ between the patients with VWD and moderate HA, nor between VWD and severe 
HA patients (p=0.14 and 0.09, respectively). This similarity in the HAL total scores occurred 
independent of age differences (Table 3). 
Subgroup analyses 
The results of the 19 included type 3 VWD patients are provided in Table 2. More than five joint 
bleeds in the same joint occurred in 84% of them, a proportion comparable to the moderate and 
severe HA patients (77% and 98% respectively). The first diagnosed joint bleed occurred later in  type 
3 VWD, compared to severe and moderate HA patients (median age at first joint bleed 9 vs. 2 vs. 4 
years respectively; statistical significance only reached between type 3 VWD and severe HA).   
The HJHS of patients with type 3 VWD appeared to be comparable to the young adults with severe 
HA (median HJHS 14 vs. 9; age adjusted RR 1.1[0.6-2.0]) and worse compared to moderate HA 
(median HJHS 14 vs. 6; age adjusted RR 0.6[0.3-1.0])(Figure 2). The use of prophylaxis was as often 
associated with arthropathy in type 3 VWD as in severe HA patients (age adjusted OR 1.8[0.5-6.6], 
Table 2). 
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Similar to the results in the whole cohort, there was a trend towards less arthropathy on X-ray in type 
3 VWD compared to severe HA (PS >3: 47% vs. 68%; age adjusted OR 0.3[0.1-1.1]). In contrast, PS >3 
appeared to occur as frequent in type 3 VWD as in moderate HA patients with verified joint bleeds 
(PS >3: 47% vs. 50%; age adjusted OR 1.0[0.2-5.2]). Type 3 VWD patients appeared to have 
radiological joint damage most often, as shown in Table 4. Due to the small numbers no statistical 
analyses were performed at joint level.  
Type 3 VWD patients reported more limitations in activities compared to those with moderate or 
severe HA (HAL total score: 77 vs. 95 and 95, p=0.03 and p=0.01, respectively).  
 
Within the whole group of VWD patients with a history of joint bleeds, FVIII levels showed a stronger 
association with joint status than VWF levels: a very low VWF activity <5 IU/dL had no impact on HJHS 
scores (median HJHS 4 vs. 5, p=0.97). But a very low FVIII level <10 IU/dL was associated with worse 
joint outcome (median HJHS 3 vs. 13, p=0.02).  
 
DISCUSSION 
Principal findings 
In this post-hoc analysis we analysed the results of three cross-sectional studies on long-term joint 
outcome after verified joint bleeds in adults with VWD (VWF activity ≤30 IU/dL) and moderate and 
severe HA. Joint health was comparable between patients with VWD and moderate HA, despite fewer 
joint bleeds and a later onset of joint bleeding in VWD. Joint health at physical examination and on X-
ray in VWD patients was only slightly better than in intensively treated young adults with severe HA. 
Joint outcome after verified joint bleeds in type 3 VWD patients appeared worse than in moderate 
HA, more comparable to intensively treated young adults with severe HA. Self-reported limitations in 
activities were similar across VWD and both moderate and severe HA patients. 
Strengths and limitations 
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The strength of this study is that we compared impact of joint bleeds in patients with VWD and HA on 
all three domains of the WHO’s ICF standard.(28) We only included patients with a verified history of 
joint bleeds, which is estimated to occur in approximately 10% of the WiN cohort.(4) Therefore, the 
results of our VWD patients cannot be generalized to all VWD patients, but only those with previously 
documented joint bleeds. Furthermore, our definition of ‘verified joint bleeds’ is limited: only 
patients with joint bleeds clinically verified by physicians were included. This may have led to 
differential misclassification of especially minor bleeds in VWD compared to HA patients.   
The main limitation is the use of data from prior studies, which prevented matching for age and year 
of birth. This is a relevant limitation since arthropathy progresses with increasing age.(33) The 
differences in joint outcome between VWD and severe HA are relatively small, which may be due to 
the younger age and more intensive treatment of the included severe HA patients. Adjusting for age 
in the analyses could only partially deal with this confounder. We were also unable to adjust for BMI 
because this was not recorded in the haemophilia cohorts. Post-hoc analysis may give rise to 
information bias. However, structural differences in PS and HJHS rating are unlikely, since agreement 
between the two radiologists was established as high and a single physiotherapist (PK) performed all 
HJHS assessments with excellent intra-rater reliability.(16;26;30) 
Strengths & limitations in relation to other studies 
Joint outcome after joint bleeds has not been compared before between VWD and HA patients. Only 
one prior study compared joint outcome between unselected patients with type 3 VWD and 
moderate HA. In this study joint ROM loss was comparable between 100 type 3 VWD and 1815 
moderate HA subjects.(34) ROM, however is only one aspect of joint function, and characterized by 
large variation and thus provides insufficient information on functioning.(28;35) We used joint health 
(HJHS), X-rays (PS) and activity/participation levels (HAL), which all are more specific instruments as 
well as validated to assess joint outcome in a broad sense. The observation of worse joint outcome in 
type 3 VWD, comparable to severe rather than moderate HA, can be explained by the selection of 
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VWD patients with verified joint bleeds in the current analyses. Furthermore, the HJHS cut-off of 10 
for arthropathy was based on a previous publication on haemophilia patients with a median age of 
24, whereas the median age of the VWD patient in the current cohort was 47 years.(17) 
As in HA, a low FVIII level is an important determinant for joint bleeding in VWD and FVIII <10 IU/dL 
at diagnosis is predictive for arthropathy.(3;13) Still, the cumulative number of joint bleeds is the 
most important predictor for arthropathy in both VWD and haemophilia.(10;13;36) In the current 
study, the number of joint bleeds was categorized with a cut-off of five as more detailed information 
could not be obtained for all patients with a history of joint bleeding.  
Possible explanations for the findings 
Compared to HA, the degree of arthropathy after joint bleeds at physical examination is remarkably 
similar in VWD, despite fewer joint bleeds and a later onset of joint bleeding. This finding could be 
explained by delayed diagnosis and inadequate recognition of joint bleeding in VWD. Another 
possible explanation is an increased tendency to develop arthropathy caused by a lack of VWF in 
addition to low FVIII levels. However, a novel finding in this study is that very low VWF activity does 
not seem to be associated with worse joint outcome independent of a low FVIII level.  
The cumulative number of joint bleeds is a major predictor of arthropathy and young cartilage is 
more vulnerable to blood induced damage.(37;38) Age related knee osteoarthritis may have 
contributed to the radiologic knee joint changes in the older VWD cohort compared to severe HA, 
since its incidence increases with age, especially over 50 years of age.(39) However, in our prior 
nested case control study, VWD patients without a history of verified joint bleeds showed less 
arthropathy than VWD patients with a joint bleed history, even with matching for age and VWD 
severity.(13)  
The similarity in self-reported limitations in activities between VWD and HA patients could partly be 
explained by the older age of the VWD patients. Furthermore, it is unknown whether other bleeding 
symptoms seen in VWD, such as severe nose bleeds, can impact the HAL score. Additionally, a 
different perspective of VWD patients on their disease-related disabilities compared to HA could be 
16 
 
responsible for this similarity in HAL scores. Differences in self-reported functional abilities in HA only 
occur between patient groups with large differences in joint health, suggesting that these patients 
have adapted well to their chronic disease.(14;40;41)  
 
Clinical implications  
The current findings clearly show that arthropathy with functional implications occurs in VWD 
patients after joint bleeds, comparable to haemophilia, especially in type 3 VWD patients. Therefore, 
the same measurement instruments can be used to assess arthropathy. Importantly, the prevention 
of arthropathy should also be a treatment goal in VWD patients presenting with recurrent joint 
bleeds. In addition, VWD patients with arthropathy probably benefit from multidisciplinary care, as 
advocated by the WFH in haemophilia.(7) Prophylaxis with VWF/FVIII concentrates has proven to be 
highly effective in reducing the number of joint bleeds in VWD.(42;43) The association of athropathy 
with the use of clotting factor prophylaxis in type 3 VWD reflects its prescription to the patients with 
most severe bleeding, but also the inability of secondary prophylaxis to prevent arthropathy. Based 
on our current and prior study results, VWD patients and their physicians should be aware of joint 
bleeding, especially in VWD patients with FVIII <10 IU/dL, and consider early treatment.(4;13) The 
finding that joint outcome after joint bleeds seems worse in type 3 VWD than in moderate HA and is 
more comparable to intensively treated severe HA patients, suggests that these VWD patients are 
candidates for prophylaxis with clotting factor concentrates in case of recurrent joint bleeds. 
Future research 
Our conclusion that outcome after verified joint bleeds in VWD is similar to moderate HA needs 
confirmation in future studies. To eliminate confounding by age and treatment intensity, future 
studies should compare joint outcome in age- and birth year matched patients with VWD and HA, 
preferably with prospective follow up. Furthermore, the relationship between arthropathy and age-
related osteoarthritis could be subject of further study. Variations in other coagulation proteins than 
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FVIII possibly contribute to the phenotypic variation of arthropathy in severe HA patients.(44) 
Analyses on the occurrence of arthropathy in VWD versus haemophilia, adjusted for the exact 
number and severity of joint bleeds at joint level might elucidate a possible role for low VWF, 
superposed on low FVIII, in the development of blood-induced arthropathy. Finally, it remains to be 
determined whether more intensive treatment of joint bleeds and/or prophylaxis can prevent 
limitations in activities, preserve quality of life and social participation in VWD patients with joint 
bleeds.  
 
In conclusion, we show that outcome after joint bleeds in VWD is similar to moderate HA 
independent of age differences, despite fewer reported joint bleeds and later onset of joint bleeding 
in VWD. Type 3 VWD patients have worst joint outcome, comparable to younger intensively treated 
severe HA patients. Furthermore, VWD patients report similar limitations in activities after joint 
bleeds as both moderate HA patients and young adults with severe HA. The clinical implication is that 
patients and physicians should be aware of joint bleeds in VWD and that proper treatment is 
necessary to prevent arthropathy, similar to haemophilia. More research is needed to identify those 
patients at the highest risk for developing arthropathy.       
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Table 1: Baseline characteristics  
  VWD type 1  VWD type 2†  VWD type 3  Moderate HA  Severe HA  
Number of patients 8 21 19 39 59 
Age (median, IQR) 58 (35-65) 45 (33-64) 40 (21-58) 39 (24-49) 25 (20-30) 
Sex (n, % male) 7 (88%) 16 (76%) 6 (32%) 39 (100%) 59 (100%) 
Age at diagnosis  
(yrs, median IQR) 
26 (1-38) 3 (0-18) 1 (0-4) 2 (0.5-7) <1 (0-1) 
FVIII (IU/dL, median 
IQR)¥ 
33 (14-39) 48 (34-53) 2 (1-4) 3 (2-4) 0 (0-0) 
VWF:RCo (IU/dL, 
median IQR)¥ 
4 (4-21) 9 (6-11) 7 (2-7) 81 (64-104) 78 (65-98) 
Annual CFC (U 
FVIII/kg/yr, median, 
IQR)* 
3 (0-42) 59 (0-103) 253 (30-840) 219 (64-462) 1995 (1491-
3110) 
Age first treatment 
(yrs, median, IQR) 
34 (6-40) 15 (4-35) 4 (2-10) 4 (0-39) 1 (0-4) 
Home treatment 
with clotting factor  
2 (25%) 5 (24%) 14 (74%) 22 (56%) 58 (98%) 
History of 
prophylaxis# 
1 (13%) 1 (5%) 11 (58%) 4 (10%) 50 (85%) 
Inhibitor (current or 
past) 
0 0 3 (16%) 1 (3%)‡ 8 (14%)‡ 
Table 1 legend: Abbreviations: IQR: interquartile range; VWD: von Willebrand disease; FVIII: clotting 
factor VIII; HA: haemophilia A; VWF:RCo: Von Willebrand factor ristocetin cofactor activity; CFC: 
clotting factor consumption. 
†VWD type 2 subtypes: 2A n=15, 2B n=5, 2N n=1, 2M n=0; ¥historically lowest levels; *Data on CFC 
use available: type 1 VWD n=8, type 2 VWD n=21, type 3 VWD n=15 (all Haemate P®, dose based of 
FVIII), moderate HA n=39, severe HA n=56; #defined as any history of at least 1 regular clotting factor 
concentrate infusion per week for at least 45 consecutive weeks; §11/13 because of joint bleeds 
including two patients still on prophylaxis at the time of the study; ‡Only low titer inhibitors of 0.3-
0.6 Bethesda Units or >0.6 BU without decreased FVIII recovery (Supplemental material).     
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Table 2: Joint outcome according to diagnosis  
 VWD type 1 VWD type 2† VWD type 3  Moderate HA  Severe HA  
Number of patients 8 21 19 39 59 
>5 joint bleeds in the 
same joint* (n, %) 
 
4¶ (50%) 5 (24%) 16 (84%) 30 (77%) 58 (98%) 
Elbow§ 1-5  
 >5  
3 (38%) 
0 (0%) 
7 (33%) 
0 (0%) 
6 (32%) 
2 (11%) 
20 (51%) 
9 (23%) 
19 (32%) 
35 (59%) 
Knee§   1-5  
 >5  
5 (63%) 
0 (0%) 
17 (81%) 
2 (10%) 
9 (47%) 
5 (26%) 
23 (59%) 
14 (36%) 
41 (70%) 
20 (34%) 
Ankle§  1-5 
 >5 
3 (38%) 
3 (38%) 
10 (48%) 
3 (14%) 
5 (26%) 
13 (68%) 
20 (51%) 
13 (33%) 
14 (24%) 
44 (75%) 
Age first JB (median, 
IQR)** 
19 (9-38) 14 (8-42) 9 (4-11) 4 (3-9) 2 (1-3) 
Orthopedic surgery# (n, 
%) 
1 (13%) 2 (10%) 8 (42%) 12 (18%) 13 (22%) 
HJHS total score‡ 
(median, IQR) 
6 (0.5-13) 2.5 (1-5) 14 (3-21) 6 (0-12) 9 (3-19)  
HJHS≥10‡ 3 (38%) 4 (19%) 12 (63%) 9 (23%) 28 (48%) 
PS >3 in at least one joint 
(n/n, %)¥ 
1 (13%) 2 (10%) 9 (47%) 5/10 (50%) 27/40 (68%) 
Arthropathy despite 
prophylaxis (%)‡  
1 (13%) 0 (0%) 11 (58%) 3 (8%) 37 (63%) 
HAL Total score‡‡ 
(median, IQR) 
85 (69-99) 92 (69-100) 77 (50-95) 95 (81-100) 95 (83-99) 
HAL Total <95 (n/total, %) 6 (75%) 12 (57%) 14/19 (74%) 17/35 (49%) 22/46 (48%) 
Table 2 legend: Abbreviations: Cum. no.: cumulative number; HA: haemophilia A; JB joint bleeds; 
HJHS Haemophilia Joint Health Score; IQR: interquartile range; HAL: Haemophilia Activities List. 
†VWD type 2 subtypes: 2A n=15, 2B n=5, 2N n=1, 2M n=0; *According to the maximum number of 
joint bleeds per joint (ankles, knees or elbows); ¶includes one patient with >5 joint bleeds in hand 
joints due to boxing (this patient also had 1-5 JB in several large joints); §according to the maximum 
number of joint bleeds in left and/or right joint (not added); **Date age 1th JB available: VWD n=48, 
moderate HA n=33, severe HA n=54; #Because of arthropathy after joint bleeds; ‡Arthropathy 
defined as a HJHS ≥10 or PS >3 of one or more joints, prophylaxis defined as any history of at least 1 
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regular clotting factor concentrate infusion per week for at least 45 consecutive weeks;‡‡n=data 
available see Figure 1; ¥Arthropathy on X-ray, specified according to joint in Table 4. 
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Table 3A and B: Age adjusted comparison of arthropathy  
A. VON WILLEBRAND DISEASE COMPARED TO MODERATE HAEMOPHILIA A 
 Multivariable regression§ 
 Negative binomial regression analyses 
Dependent variable Rate Ratio¥ 95% CI p-value 
HJHS  0.9 0.5-1.4 0.60 
HJHS corrected for VWF inhibitors 1.0 0.6-1.6 1.0 
 Logistic regression analyses 
 Odds Ratio‡ 95% CI p-value 
Cum no. JB >5 overall  0.2 0.1-0.7 <0.01 
HAL <95  1.7 0.7-4.5 0.25 
PS >3  0.3 0.1-1.4 0.13 
 
B. VON WILLEBRAND DISEASE COMPARED TO SEVERE HAEMOPHILIA A 
 Multivariable regression§ 
 Negative binomial regression analyses 
 Rate Ratio¥ 95% CI p-value 
HJHS  1.8 1.1-2.9 0.02 
HJHS corrected for VWF inhibitors 2.1 1.3-3.5 <0.01 
 Logistic regression analyses 
 Odds Ratio‡ 95% CI p-value 
Cum no. JB >5 overall  0.02 0.002-0.1 <0.01 
HAL <95  1.3 0.5-3.5 0.63 
PS >3# 0.1 0.03-0.3 <0.01 
Table 3A and B legend: Abbreviations: CI: 95% confidence interval; RR: rate ratio; OR: odds ratio; 
HJHS: Heamophilia Joint Health Score; Cum no. JB: cumulative number of joint bleeds in at least one 
joint; HAL: Heamophilia Activities List; PS: Pettersson score (X-ray score of ankles, elbows and knees). 
§all analyses are adjusted for age and with VWD as the reference category; ¥The rate ratio indicates 
that, as compared to VWD, the HA patients had on average RR times more (of less if RR <1) HJHS 
points, independent of age differences and ..; ‡The odds ratio indicates that the chance (odds) of 
VWD patients to have functional limitations or … is OR times higher (or lower if OR <1) than the HA 
patients, independent of age differences; #arthropathy on X-ray of at least one individual  joint. 
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Table 4: Arthropathy on X-rays of joints with prior bleeds  
 
 VWD Moderate HA Severe HA Type 3 VWD 
Knees PS >3/total* (%) 
Knees JB >5/total (%) 
5/46 (11%) 
8/96 (8%) 
0/10 (0%) 
16/78 (21%) 
7/56 (13%) 
27/118 (23%) 
3/10 (30%) 
6/38 (16%) 
Ankles PS >3/total* (%) 
Ankles JB >5/total (%) 
13/52 (25%) 
30/96 (31%) 
3/13 (23%) 
20/78 (26%) 
32/73 (44%) 
65/118 (55%) 
10/20 (50%) 
21/38 (55%) 
Elbows PS >3/total* (%) 
Elbows JB >5/total 
3/17 (18%) 
3/96 (3%) 
6/11 (55%) 
12/78 (15%) 
11/58 (19%) 
44/118 (37%) 
3/4 (75%) 
3/38 (8%) 
Total proportion PS>3 of joints 
with JB>5 (%)¥ 
21/41 9/48 50/136 16/30 
Table 4 legend: Abbreviations: VWD: Von Willebrand disease; HA: haemophilia A; PS: Pettersson 
score; JB: joint bleeds; pts: patients.*total is n joints with prior bleeds and an X-ray score available (X-
rays were taken from joints with prior bleeds and controls as previously reported(13)); †in the at least 
one joint; ¥ less X-rays available for analysis in HA compared to VWD. 
 
